AVITA Medical reports PermeaDerm study results with 70% economic advantage
AVITA Medical says its PermeaDerm study demonstrates a 70% economic advantage versus allograft and reports comparable clinical outcomes.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.